A nurse prepares a dose of the Pfizer-BioNTech Covid-19 vaccine at the Northern General Hospital in Sheffield, UK, on December 8. Photo: AFP A nurse prepares a dose of the Pfizer-BioNTech Covid-19 vaccine at the Northern General Hospital in Sheffield, UK, on December 8. Photo: AFP
A nurse prepares a dose of the Pfizer-BioNTech Covid-19 vaccine at the Northern General Hospital in Sheffield, UK, on December 8. Photo: AFP
Sylvia Sheng
Opinion

Opinion

Sylvia Sheng

Vaccine optimism must be tempered with attention to coronavirus resurgence

  • While market sentiment has been dominated by hope that encouraging vaccine results will lead to economic recovery, the resurgence of the virus, especially in the US and Europe, means policy support must continue

A nurse prepares a dose of the Pfizer-BioNTech Covid-19 vaccine at the Northern General Hospital in Sheffield, UK, on December 8. Photo: AFP A nurse prepares a dose of the Pfizer-BioNTech Covid-19 vaccine at the Northern General Hospital in Sheffield, UK, on December 8. Photo: AFP
A nurse prepares a dose of the Pfizer-BioNTech Covid-19 vaccine at the Northern General Hospital in Sheffield, UK, on December 8. Photo: AFP
READ FULL ARTICLE
Sylvia Sheng

Sylvia Sheng

Sylvia Sheng, vice president, is a global strategist on the multi-asset solutions team, responsible for communicating the group's economic and asset allocation strategy, based in Hong Kong. Prior to joining J.P. Morgan, she worked as a China and Asia economist at Bank of America Merrill Lynch. She has a PhD in economics from the University of Cambridge and an MPhil and BA in economics from the same university.